MNMD (Mind Medicine) Cash, Cash Equivalents, Marketable Securities : $295.28 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Mind Medicine Cash, Cash Equivalents, Marketable Securities?

Mind Medicine's quarterly cash, cash equivalents, marketable securities declined from Mar. 2024 ($252.33 Mil) to Jun. 2024 ($243.13 Mil) but then increased from Jun. 2024 ($243.13 Mil) to Sep. 2024 ($295.28 Mil).

Mind Medicine's annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($133.54 Mil) to Dec. 2022 ($142.14 Mil) but then declined from Dec. 2022 ($142.14 Mil) to Dec. 2023 ($99.70 Mil).

Mind Medicine Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Mind Medicine's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine Cash, Cash Equivalents, Marketable Securities Chart

Mind Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

80.09

133.54

142.14

99.70

Mind Medicine Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															117.70	99.70	252.33	243.13	295.28

Mind Medicine Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Mind Medicine (NAS:MNMD) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Mind Medicine Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Mind Medicine's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Mind Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (NAS:MNMD) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

MMQ:Germany

Address

One World Trade Center, Suite 8500, New York, NY, USA, 10007

Website

https://www.mindmed.co

Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.

Executives

Mark Sullivan	officer: Chief Legal Officer	1000 BISHOPS GATE BOULEVARD, SUITE 300, MOUNT LAUREL NJ 08054
Robert Barrow	director, officer: Chief Executive Officer	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Dan Karlin	officer: Chief Medical Officer	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Carrie Liao	officer: VP, Controller&Acct Principal	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
David W Gryska	director	749 N MARY AVE, SUNNYVALE CA 94085
Schond L. Greenway	officer: Chief Financial Officer	C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850
Carol A Vallone	director	490 SUMMER STREET, MANCHESTER MA 01944
Andreas Krebs	director	5 GIRALDA FARMS, MADISON NJ 07940
Suzanne Louise Bruhn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Roger Crystal	director	445 PARK AVE, 10TH FL., NEW YORK NY 10022
Cynthia W. Hu	officer: Chief Legal Officer&Secretary	6440 WINDERMERE, NORTH BETHESDA MD 20852
Brigid Makes	director	20245 SW 95TH AVENUE, TUALATIN OR 97062
Sarah Y Vinson	director	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Stephen L Hurst	director	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Miri Halperin Wernli	director, officer: Executive President	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007